LYBALVI Drug Patent Profile

Which patents cover Lybalvi, and when can generic versions of Lybalvi launch?

Lybalvi is a drug marketed by Alkermes Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in twenty countries.

The generic ingredient in LYBALVI is olanzapine; samidorphan l-malate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine; samidorphan l-malate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lybalvi

Lybalvi was eligible for patent challenges on May 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 12, 2041. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LYBALVI

International Patents:	60
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LYBALVI

Paragraph IV (Patent) Challenges for LYBALVI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LYBALVI	Tablets	olanzapine; samidorphan l-malate	5 mg/10 mg 10 mg/10 mg 15 mg/10 mg 20 mg/10 mg	213378	3	2025-05-28

US Patents and Regulatory Information for LYBALVI

LYBALVI is protected by twenty-one US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021		RX	Yes	No			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No				Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No

International Patents for LYBALVI

When does loss-of-exclusivity occur for LYBALVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LYBALVI around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2506712
Slovenia	3446565
European Patent Office	2251330	4-Hydroxybenzomorphanes (4-Hydroxybenzomorphans)
Japan	5198067
Portugal	2608670
European Patent Office	4306164	MÉTHODES DE TRAITEMENT DE LA PRISE DE POIDS INDUITE PAR DES ANTIPSYCHOTIQUES (METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN)

Supplementary Protection Certificates for LYBALVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927

LYBALVI (olanzapine/samidorphan): Investment Scenario and Fundamentals Analysis

Last updated: April 23, 2026

What is LYBALVI and what does it monetize?

LYBALVI is an oral, fixed-dose combination antipsychotic indicated for schizophrenia and bipolar I disorder. It combines olanzapine with samidorphan, an opioid receptor modulator intended to reduce olanzapine-associated weight gain and metabolic risk.

Product economics drivers (what markets price)

1. Net sales momentum and payer uptake in schizophrenia and bipolar I
2. Relative value vs olanzapine generics using total managed-care cost (formulary placement, prior authorization, utilization controls)
3. Ongoing label expansion and real-world persistence (switch rates from olanzapine)
4. Competitive pressure from other schizophrenia and bipolar branded therapies and LAIs

What is the commercial state of LYBALVI?

A fundamentals view requires sales, channel, and geography, but no sales trajectory, channel mix, or latest payer coverage data is present in the information provided here. Without hard market performance inputs, a complete investment-grade analysis cannot be produced.

What is the competitive landscape for olanzapine-based antipsychotic therapy?

Direct substitution pressure

• Generic olanzapine is the principal pricing benchmark. Managed care often uses generic olanzapine as the anchor for step therapy and tiering.
• The clinical and health economics case for LYBALVI must translate into formulary access despite higher acquisition cost.

Therapeutic-area substitutes

• Second-generation antipsychotics (oral and long-acting injectables) compete on symptom control, tolerability, adherence, and metabolic risk.
• LAIs can win adherence-driven value even if weight/metabolic profiles differ.

Investor relevance

For branded combo products, the key is whether formulary committees treat LYBALVI as a “cost-offset” option (reduced weight/metabolic complications) or as an “add-cost” option (premium without measurable savings). That decision governs volume capture.

How strong is the patent and exclusivity position?

No patent term, expiration dates, regulatory exclusivity, or Orange Book-style event timeline is included in the information provided here. A correct investment view depends on legal life (primary and secondary patents), exclusivity runway, and risk of generic entry.

What is the regulatory and lifecycle risk profile?

No FDA postmarketing commitments, safety signals, label changes, or risk management data are included here. For LYBALVI, lifecycle risk assessment must cover:

• safety tolerability (including metabolic, sedation, and opioid-related adverse events)
• REMS needs (if any) and whether they constrain access
• drug-drug interaction burden that affects use in comorbid populations

Those specifics are not present in the input.

What clinical value proposition supports formulary access?

The investment question is not whether LYBALVI is clinically effective; it is whether its incremental benefit is recognized by payers in real-world outcomes.

Key payer decision criteria typically include:

• Weight gain reduction vs olanzapine
• Metabolic marker improvement (lipids, glucose, insulin resistance)
• Persistence and switching (fewer discontinuations or reversals)
• Downstream medical cost offsets (diabetes, cardiovascular events)

However, without quantitative trial endpoints, comparative claims, or real-world evidence in the provided material, a precise fundamentals-backed valuation cannot be completed.

What should an investor underwrite: demand, pricing, or cost offsets?

A robust underwriting model for LYBALVI would usually separate:

• Demand: incremental adoption versus generic olanzapine
• Pricing: net price after rebates and contracting
• Cost offsets: avoided weight and metabolic sequelae

That model cannot be parameterized without sales/contracting data, rebate assumptions, and outcomes evidence.

Investment scenario framework (what to model)

Even without numerical inputs, the scenario architecture for a combination antipsychotic like LYBALVI is consistent:

1) Base case (commercial success with controlled churn from generics)

• Gradual formulary expansion in schizophrenia and bipolar I
• Switch from olanzapine in patients with weight/metabolic concerns
• Stabilization in payer coverage after contracting cycles

2) Upside (payer endorsement as a cost-offset)

• Faster uptake with less restrictive PA criteria
• Demonstrated reduced downstream utilization (diabetes, obesity-related care)
• Broader geographic coverage and improved adherence

3) Downside (generic anchoring limits volume)

• Step edits and tiering keep volume growth capped
• High rebate pressure erodes net price
• Clinical adoption does not translate into measurable health economics for plan models

To produce an investment-grade conclusion, each scenario requires numeric anchor points (current sales run rate, channel distribution, net price trajectory, and patent-driven generic timelines). Those anchors are not provided.

Key takeaways

• LYBALVI is a fixed-dose combination of olanzapine and samidorphan targeting schizophrenia and bipolar I with a commercial thesis centered on weight/metabolic risk mitigation versus olanzapine.
• The investment outcome is driven by whether payers treat LYBALVI as a premium with measurable cost offsets or as an add-cost alternative constrained by generic olanzapine.
• A complete fundamentals analysis (forecast, patent runway, generic entry risk, and payer coverage economics) cannot be produced from the information provided here.

FAQs

1) What is LYBALVI’s core mechanism in one line?

It is an olanzapine-based antipsychotic combined with samidorphan intended to reduce olanzapine-associated weight/metabolic burden.

2) What is the biggest pricing benchmark for LYBALVI?

Generic olanzapine.

3) What determines whether LYBALVI wins formulary placement?

Net value versus generic olanzapine using plan-relevant outcomes (weight/metabolic and downstream costs), plus contracting leverage.

4) What are the major investment risks for LYBALVI?

Generic anchoring from olanzapine, payer contracting pressure, and any lifecycle limitations tied to safety or label constraints.

5) What data should drive an investment-grade forecast for LYBALVI?

Current net sales run rate, net price and rebate rates, payer coverage and PA criteria, persistence/switching rates, and the full patent/exclusivity event calendar.

References

[1] (No sources were provided in the input.)